Antibiotic susceptibility of Staphylococcus aureus strains responsible for cutaneous infections in the community;Sensibilité aux antibiotiques des souches de Staphylococcus aureus responsables d'infections cutanées communautaires

Annales de Dermatologie et de Venereologie

Volumn 135, Issue 1, 2008, Pages 13-19

  Bernard, P ^a   Jarlier, V ^b   Santerre Henriksen, A ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LEO PHARMA A S   (Denmark)

Author keywords

Community acquired skin infections; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; OXACILLIN; PENICILLIN G; PSEUDOMONIC ACID; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; ECTHYMA; FEMALE; FOLLICULITIS; FURUNCULOSIS; HOSPITALIZATION; HUMAN; IMPETIGO; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT; PARONYCHIA; PROSPECTIVE STUDY; QUESTIONNAIRE; SECONDARY INFECTION; SKIN INFECTION; CLINICAL TRIAL; COMMUNICABLE DISEASE; FRANCE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 43049183665     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2007.06.004     Document Type: Article

References (26)

1. ®) versus oxacilline dans le traitement des pyodermites superficielles : résultats d'une étude randomisée multicentrique chez 293 malades ambulatoires. Ann Dermatol Venereol 124 (1997) 384-389
2. Claudy A et Groupe français d'étude. Pyodermites superficielles nécessitant une antibiothérapie orale. Presse Med 30 (2001) 364-368
3. Lorette G., Beaulieu P., Bismuth R., Duru G., Guihard W., Lemaitre M., et al. Infections cutanées communautaires : bactéries en cause et sensibilité aux antibiotiques. Ann Dermatol Venereol 130 (2003) 723-728
4. Chosidow O., Bernard P., Berbis P., Humbert P., Crickx B., and Jarlier V. Cloxacillin versus pristinamycin for superficial pyodermas: a randomised, open-label, non-inferiority study. Dermatology 210 (2005) 370-374
5. Zetola N., Francis J.S., Nuermberger E.L., and Bishai W.R. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Inf Dis 5 (2005) 275-286
6. Elston D.M. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol 56 (2007) 1-16
7. NCCLS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-sixth edition M7-A6 with the MIC testing; January 2005.
8. Groom A.V., Wolsey D.H., Naimi T.S., Smith K., Johnson S., Boxrud D., et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 286 (2001) 1201-1205
9. Naimi T.S., Ledell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., et al. Comparison of community - and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
10. Baggett H.C., Henessy T.W., Rudolph K., Bruden B., Reasonover A., Parkinson A., et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leucocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 189 (2004) 1565-1573
11. Diep B.A., Sensabaugh G.F., Somboona N.S., Carleton H.A., and Perdreau-Remington F. Widespsread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 42 (2004) 2080-2084
12. Fridkin S.K., Hageman J.C., Morisson M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
13. Quentin C., Grobost F., Fischer I., Dutilh B., Brochet J.P., Jullin J., et al. Profil de résistance aux antibiotiques de Staphylococcus aureus en milieu urbain : étude sur 6 mois en Aquitaine. Pathol Biol 49 (2001) 33-40
14. Lucet J.C., Chevret S., Durand-Zaleski I., Chastang C., and Regnier B. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 163 (2003) 181-188
15. Del Giudice P., Blanc V., Durupt G., Bes M., Martinez J.P., Counillon E., et al. Emergence of two populations of methicillin-resistant Staphylococcus aureus with distinct epidemiological, clinical and biological features, isolated from patients with community-acquired skin infections. Br J Dermatol 154 (2006) 118-124
16. Jones M.E., Scmitz F.J., Fluit A.C., Acar J., Gupta R., and Verhoef J. Frequency of occurence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Program SENTRY Participants Group. Eur J Clin Microbiol Infect Dis 18 (1999) 403-408
17. Gales A.C., Jones R.N., Pfaller M.A., Gordon K.A., and Sader H.S. Two-year assessment of the pathogen frequency and microbial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American Hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997-1998. Int J Infect Dis 4 (2000) 75-84
18. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666-674
19. Ferech M., Coenen S., Malhotra-Kumar S., Dvorakova K., Hendrickx E., Suetens C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 58 (2006) 401-407
20. Agence française de sécurité sanitaire des produits de santé. Prescription des antibiotiques par voie locale dans les infections cutanées bactériennes primitives et secondaires. Ann Dermatol Venereol 2004;131:1018-21.
21. Ravenscroft J.C., Layton A., and Barham M. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin Exp Dermatol 25 (2000) 327-330
22. Ravenscroft J.C., Layton A., Eady A.M., Murtagh M.S., Coates P., Walker M., et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 148 (2003) 1010-1017
23. Brown E.M., and Thomas P. Fusidic resistance Staphylococcus aureus isolates. Lancet 359 (2002) 803
24. Denton M, O'Connell B, Bernard P, Jarlier V, Williams Z, Santerre-Henriksen A. The EPISA study: Antimicrobial Susceptibility of Staphylococcus aureus causing Primary or Secondary Skin and Soft Tissue Infections in the community in France, the United Kingdom and Ireland. J Antimicrob Chemother (in press)
25. Afset J.E., and Maeland J.A. Susceptibility of skin and soft-tissue isolates of Staphylococcus aureus and Streptococcus pyogenes to topical antibiotics. Indication of a clonal spread of fusidic acid-resistant Staphylococcus aureus. Scand J Infect Dis 35 (2003) 84-89
26. Lucet J.C., and Descamps V. Pour un usage raisonné de la mupirocine. Ann Dermatol Venereol 127 (2000) 365-366